Botulinum Toxin Confers Radioprotection in Murine Salivary Glands

Youssef Zeidan, Nan Xiao, Hongbin Cao, Christina Kong, Quynh Thu Le, Davud Sirjani

Research output: Contribution to journalArticle

5 Scopus citations


Purpose: Xerostomia is a common radiation sequela, which has a negative impact on the quality of life of patients with head and neck cancer. Current treatment strategies offer only partial relief. Botulinum toxins (BTX) have been successfully used in treating a variety of radiation sequelae such as cystitis, proctitis, fibrosis, and facial pain. The purpose of this study was to evaluate the effect of BTX on radiation-induced salivary gland damage. Methods and Materials: We used a previously established model for murine salivary gland irradiation (IR). The submandibular glands (SMGs) of C5BL/6 mice (n=6/group) were injected with saline or BTX 72 hours before receiving 15 Gy of focal irradiation. Saliva flow was measured 3, 7, and 28 days after treatment. The SMGs were collected for immunohistochemistry, confocal microscopy, and Western blotting. A cytokine array consisting of 40 different mouse cytokines was used to evaluate cytokine profiles after radiation treatment. Results: Irradiated mice showed a 50% reduction in saliva flow after 3 days, whereas mice preinjected with BTX had 25% reduction in saliva flow (P

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology Biology Physics
StateAccepted/In press - Oct 7 2015

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Fingerprint Dive into the research topics of 'Botulinum Toxin Confers Radioprotection in Murine Salivary Glands'. Together they form a unique fingerprint.

  • Cite this